• Course information

    Place of training
    E-Learning (Online)
    Language
    It is the intention of the course coordinator to deliver this training alternately in English and French. Please watch this site for details regarding the language that the course will be conducted in.
    Target group
    This is a training focusing only on medical doctors actively treating people with DR TB
    Number of participants
    There is usually a quota system for each OC, with the ultimate decision being made based on meeting the selection criteria for attendance.
    Duration
    35 - 40 hours
    Enrolment

    An application form will accompany the course announcement closer to the time of the course itself. Please watch this site for details so that you can ensure, via your HRCo or pool manager, that you are able to apply timeously.

    Dates
    May 24 to June 16, 2022. The applications for this course have now closed. Another course, in French, will be held in the fourth quarter in 2022. Details will be announced on this site.
    Content

    This training has changed from a face-to-face training in Cape Town to an online hybrid course, combining self-study and online interactive sessions with DR TB experts. Click on the link to view the content of the DR TB workshop.

  • The general objective of training

    To improve the quality DR-TB clinical care in MSF supported projects by:

    - Sharing experiences and improve knowledge of clinicians in diagnosing and treating DR-TB 
    - Addressing current problems faced by clinicians including choice of regimen, monitoring, adverse events, lack of response to treatment
    - Reviewing different treatment delivery and patient centred strategies that can improve both outcomes and patient experience of DR-TB treatment

  • Specific learning outcomes

    On successful completion of this training course participants will be able to: 

    - identify eligible patients for all oral shorter and longer DR-TB treatment 
    - build an all-oral longer individualised DR-TB regimen according to latest recommendations for newly diagnosed DRTB patients 
    - closely monitor a patient on treatment for potential adverse events and manage them if they should occur
    - record adverse events experienced by DR-TB for pharmacovigilance correctly
    - correctly record and report DR-TB treatment outcomes 
    - work with a team to support patients to be adherence to treatment, including the explanation of adverse events to patients 
    - identify and manage paediatric DR-TB cases and know where and when to ask for help